The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 ...

The integration of Bruton tyrosine kinase (BTK) inhibitors into first-line treatment regimens, in combination with immunochemotherapy, constitutes the new standard of care following the recent ...

Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year before it entered the second part of a phase 1/2 lymphoma study. | Regeneron has given up on a CAR-T candidate acquired ...

The addition of an investigational therapeutic cancer vaccine to first-line pembrolizumab exhibited activity among patients ...

Human interleukin-26 (IL-26) is linked to intestinal inflammation and is bactericidal in vitro. This study uses zebrafish as ...

The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.

Age-related changes in blood stem cells are linked to decreased platelet factor 4, marking a critical finding for treating ...

As our hairs go gray and our muscles weaken with age, our immune system also changes. In particular, the stem cells that ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) for sonrotoclax, a ...

As the company continues its optimal dosing investigations, additional infusions have been given to the second and third ...

Study’s Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial ...